116 related articles for article (PubMed ID: 2440556)
21. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
22. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Bolon I; Gouyer V; Devouassoux M; Vandenbunder B; Wernert N; Moro D; Brambilla C; Brambilla E
Am J Pathol; 1995 Nov; 147(5):1298-310. PubMed ID: 7485393
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
Busso N; Belin D; Failly-Crépin C; Vassalli JD
Cancer Res; 1987 Jan; 47(2):364-70. PubMed ID: 3098408
[TBL] [Abstract][Full Text] [Related]
25. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
26. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
27. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
28. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
Michel JB; Quertermous T
J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
[TBL] [Abstract][Full Text] [Related]
29. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
30. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
31. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
[TBL] [Abstract][Full Text] [Related]
32. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Gohji K; Nakajima M; Boyd D; Dinney CP; Bucana CD; Kitazana S; Kamidono S; Fidler IJ
Am J Pathol; 1997 Dec; 151(6):1655-61. PubMed ID: 9403716
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Li XF; Yan PJ; Shao ZM
Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
[TBL] [Abstract][Full Text] [Related]
34. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
36. Induction of fibronectin mRNA by urokinase- and tissue-type plasminogen activator in human skin fibroblasts: differential role of u-PA and t-PA at the fibronectin protein level.
De Petro G; Tavian D; Marchina E; Barlati S
Biol Chem; 2002 Jan; 383(1):177-87. PubMed ID: 11928812
[TBL] [Abstract][Full Text] [Related]
37. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
38. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Rømer J; Pyke C; Lund LR; Ralfkiaer E; Danø K
J Invest Dermatol; 2001 Mar; 116(3):353-8. PubMed ID: 11231307
[TBL] [Abstract][Full Text] [Related]
39. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Petruzzelli GJ; Snyderman CH; Johnson JT
Arch Otolaryngol Head Neck Surg; 1994 Sep; 120(9):989-92. PubMed ID: 8074827
[TBL] [Abstract][Full Text] [Related]
40. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
Yoshino H; Endo Y; Watanabe Y; Sasaki T
Br J Cancer; 1998 Sep; 78(6):833-9. PubMed ID: 9743310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
